Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RVPH Stock Forecast 2026-2027
$0.35
Current Price
$40.90M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to RVPH Price Targets
+4,471.4%
To High Target of $16.00
+757.1%
To Median Target of $3.00
+328.6%
To Low Target of $1.50
RVPH Price Momentum
-5.4%
1 Week Change
-44.4%
1 Month Change
-80.7%
1 Year Change
+25.0%
Year-to-Date Change
-83.7%
From 52W High of $2.15
+40.0%
From 52W Low of $0.25
📊 TOP ANALYST CALLS
Did RVPH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Reviva Pharmaceuticals is one of their latest high-conviction picks.
Latest RVPH Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, RVPH has a bullish consensus with a median price target of $3.00 (ranging from $1.50 to $16.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $0.35, the median forecast implies a 757.1% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from James Molloy at Alliance Global Partners, projecting a 4,471.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RVPH Analyst Ratings
7
Buy
0
Hold
0
Sell
RVPH Price Target Range
Low
$1.50
Average
$3.00
High
$16.00
Current: $0.35
Latest RVPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RVPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 5, 2026 | Chardan Capital | Keay Nakae | Buy | Maintains | $2.00 |
| Dec 23, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $4.00 |
| Dec 23, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $2.00 |
| Nov 19, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $2.00 |
| Oct 28, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $2.00 |
| Oct 27, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $4.00 |
| Sep 29, 2025 | Chardan Capital | Rudy Li | Buy | Initiates | $2.00 |
| Sep 19, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $2.00 |
| Sep 15, 2025 | Benchmark | Bruce D. Jackson | Speculative Buy | Maintains | $7.00 |
| Aug 18, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $3.00 |
| Aug 18, 2025 | Roth Capital | Boobalan Pachaiyappan | Buy | Reiterates | $3.00 |
| Aug 15, 2025 | Maxim Group | Jason McCarthy | Buy | Maintains | $2.00 |
| Jun 27, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $3.00 |
| Jun 3, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $3.00 |
| May 20, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $3.00 |
| Apr 24, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $8.00 |
| Apr 1, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $8.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $11.00 |
| Jan 21, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $15.00 |
| Jan 10, 2025 | Maxim Group | Jason McCarthy | Buy | Upgrade | $7.00 |
Reviva Pharmaceuticals Holdings, Inc. (RVPH) Competitors
The following stocks are similar to Reviva Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RVPH
Reviva Pharmaceuticals
mkt cap
39.73M
Reviva Pharmaceuticals Holdings, Inc. (RVPH) Financial Data
Reviva Pharmaceuticals Holdings, Inc. has a market capitalization of $40.90M with a P/E ratio of -0.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -3,682.0%.
Valuation Metrics
Market Cap
$40.90M
Enterprise Value
$27.66M
P/E Ratio
-0.4x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+32.9%
Current Ratio
1.4x
Debt/Equity
0.0x
ROE
-3,682.0%
ROA
-130.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) Business Model
About Reviva Pharmaceuticals Holdings, Inc.
What They Do
Develops drugs for mental health disorders.
Business Model
Reviva Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of new therapeutic drugs. The company generates revenue by advancing its product candidates through clinical trials, seeking regulatory approvals, and eventually commercializing its innovative treatments aimed at central nervous system diseases.
Additional Information
The company's lead product candidate targets schizophrenia and is designed to offer better efficacy and tolerability than existing treatments. Reviva is committed to addressing unmet medical needs in mental health, thereby contributing significantly to the pharmaceutical industry and enhancing patients' quality of life.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
14
CEO
Dr. Laxminarayan Bhat Ph.D.
Country
United States
IPO Year
2018
Website
www.revivapharma.comReviva Pharmaceuticals Holdings, Inc. (RVPH) Latest News & Analysis
Latest News
Quick Summary
Reviva Pharmaceuticals (NASDAQ: RVPH) will present at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026. The company focuses on CNS, inflammatory, and cardiometabolic therapies.
Why It Matters
Reviva Pharmaceuticals' presentation at a prominent neuroscience forum could attract attention to its pipeline, influencing stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug
22 days ago
Quick Summary
Reviva Pharmaceuticals (NASDAQ: RVPH) announced a regulatory update after a pre-NDA meeting with the FDA on Tuesday.
Why It Matters
Regulatory updates from Reviva Pharmaceuticals can impact stock performance by influencing investor confidence in upcoming drug approvals and market potential.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
The FDA recommends a second Phase 3 trial for brilaroxazine to gather more efficacy and safety data before the NDA submission for schizophrenia treatment.
Why It Matters
The FDA's recommendation for a second Phase 3 trial delays the NDA submission for brilaroxazine, potentially impacting the timeline for approval and revenue projections for the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Reviva Pharmaceuticals plans a pre-NDA meeting with the FDA for brilaroxazine in Q4 2025, with a potential NDA submission for schizophrenia in Q2 2026. A European patent for pulmonary fibrosis use has been granted.
Why It Matters
The FDA meeting and NDA timeline for brilaroxazine signal potential market entry, while the European patent strengthens Reviva's competitive position, influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Reviva Pharmaceuticals (NASDAQ: RVPH) will present negative symptom data for brilaroxazine from Phase 3 trials at the CNS Summit 2025, scheduled for November 2-5 in Boston.
Why It Matters
The announcement of negative trial results for brilaroxazine may impact Reviva's stock price and investor confidence, highlighting risks in its pipeline and potential challenges in market approval.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Reviva Pharmaceuticals (NASDAQ: RVPH) will have CEO Laxminarayan Bhat participate in a webinar on October 10, 2025, hosted by A.G.P./Alliance Global Partners.
Why It Matters
Reviva's CEO participating in a KOL webinar may signal upcoming developments or insights into their therapies, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RVPH Stock
What is Reviva Pharmaceuticals Holdings, Inc.'s (RVPH) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Reviva Pharmaceuticals Holdings, Inc. (RVPH) has a median price target of $3.00. The highest price target is $16.00 and the lowest is $1.50.
Is RVPH stock a good investment in 2026?
According to current analyst ratings, RVPH has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.35. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RVPH stock?
Wall Street analysts predict RVPH stock could reach $3.00 in the next 12 months. This represents a 757.1% increase from the current price of $0.35. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Reviva Pharmaceuticals Holdings, Inc.'s business model?
Reviva Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of new therapeutic drugs. The company generates revenue by advancing its product candidates through clinical trials, seeking regulatory approvals, and eventually commercializing its innovative treatments aimed at central nervous system diseases.
What is the highest forecasted price for RVPH Reviva Pharmaceuticals Holdings, Inc.?
The highest price target for RVPH is $16.00 from James Molloy at Alliance Global Partners, which represents a 4,471.4% increase from the current price of $0.35.
What is the lowest forecasted price for RVPH Reviva Pharmaceuticals Holdings, Inc.?
The lowest price target for RVPH is $1.50 from at , which represents a 328.6% increase from the current price of $0.35.
What is the overall RVPH consensus from analysts for Reviva Pharmaceuticals Holdings, Inc.?
The overall analyst consensus for RVPH is bullish. Out of 11 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are RVPH stock price projections?
Stock price projections, including those for Reviva Pharmaceuticals Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 4:12 AM UTC